Patents by Inventor Pietro Taverna

Pietro Taverna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DRUG COMBINATIONS
    Publication number: 20200009247
    Abstract: The invention provides combinations of derivatives of decitabine and other active agents, including T-cell activating agents, cancer vaccines, and adjuvants. Some derivatives of decitabine exhibit superior chemical stability and shelf life, with similar physiological activity. Methods of treating one or more myelodysplasia syndromes, cancers, haematological disorders, or diseases associated with abnormal haemoglobin synthesis using the combinations are described.
    Type: Application
    Filed: July 17, 2019
    Publication date: January 9, 2020
    Inventors: Mohammad AZAB, Pietro TAVERNA, Alessia COVRE, Sandra CORAL
  • DRUG COMBINATIONS
    Publication number: 20160015805
    Abstract: The invention provides combinations of derivatives of decitabine and other active agents, including T-cell activating agents, cancer vaccines, and adjuvants. Some derivatives of decitabine exhibit superior chemical stability and shelf life, with similar physiological activity. Methods of treating one or more myelodysplasia syndromes, cancers, haematological disorders, or diseases associated with abnormal haemoglobin synthesis using the combinations are described.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 21, 2016
    Inventors: Mohammad AZAB, Pietro TAVERNA, Alessia COVRE, Sandra CORAL
  • Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
    Publication number: 20030229004
    Abstract: Methods and compositions are providing for modulating cellular activity. In the subject methods, target cells are contacted with both a BER inhibitor and a sensitizing agent, e.g., either a radiosensitizing agent and/or a chemotherapeutic agent, where the cells may optionally be contacted with a DSBR inhibitor, such as a RAD inhibitor, e.g., a RAD51 inhibitor. Also provided are pharmaceutical preparations, as well as kits thereof, that find use in practicing the subject methods.
    Type: Application
    Filed: March 20, 2003
    Publication date: December 11, 2003
    Applicant: Pangene Corporation
    Inventors: David A. Zarling, Gurucharan Reddy, Pietro Taverna